7356results about How to "Reduce release" patented technology

The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

An object of the present invention is to provide an EL display device, which has a high operating performance and reliability. A third passivation film 45 is disposed under an EL element 203 which comprises a pixel electrode (anode) 46, and EL layer 47 and a cathode 48, to make a structure in which heat generated by the EL element 203 is radiated. Further, the third passivation film 45 prevents alkali metals within the EL element 203 from diffusing into the TFTs side, and prevents moisture and oxygen of the TFTs side from penetrating into the EL element 203. More preferably, heat radiating effect is given to a fourth passivation film 50 to make the EL element 203 to be enclosed by heat radiating layers.

A novel composition for the use as snuff in the oral cavity, the composition comprising tobacco and / or a tobacco substitute encapsulated in a membrane material comprising one or more membranes at least one of which being water permeable and water-insoluble. A novel composition enables a selective release of e.g. nicotine while it at the same time reduces the release of substances, which normally lead to unwanted side effects. The novel compositions may be used as a healthier alternative to snuff and other tobacco products such as, e.g., cigarettes, cigars and pipe. Methods for giving up smoking, reducing nicotine craving, reducing side effects normally related to smoking and snuffing of tobacco as welt a method for the preparation of a composition according to the invention.

The invention provides tools, materials and related methods to surgically access the suprachoroidal space of an eye for the purpose of performing minimally invasive surgery or to deliver drugs to the eye. The invention provides a flexible microcannula device (11, 13) that may be placed into the suprachoroidal space (12, 14) through a small incision (12A) of the overlying tissues, maneuvered into the appropriate region of the space, and then activated to treat tissues adjacent to the distal tip of the device.

Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients.

Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.

Methods and apparatus for the remote coagulation of blood using high-intensity focused ultrasound (HIFU) are provided. A remote hemostasis method comprises identifying a site of internal bleeding and focusing therapeutic ultrasound energy on the site, the energy being focused through an intervening tissue. An apparatus for producing remote hemostasis comprises a focused therapeutic ultrasound radiating surface and a sensor for identifying a site of internal bleeding, with a registration means coupled to the radiating surface and the sensor to bring a focal target and the bleeding site into alignment. The sensor generally comprises a Doppler imaging display. Hemostasis enhancing agents may be introduced to the site for actuation by the ultrasound energy.

An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble, but enzymatically degradable by enzymes present in the human gastrointestinal tract. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.

The invention relates to an inorganic / organic nano-composite antibacterial and application of fiber product thereof. 0.01-20 proportions of inorganic antibacterial, 0.01-35 proportions of organic antibacterial, 0.0001-0.4 proportion of inorganic / organic antibacterial compatibility finishing agent, 0.05-40 proportions of macromolecule bond, 0.0001-0.4 proportion of stabilizer that prevents color change of the inorganic antibacterial, 0.1-30 proportions of high efficiency emulsifying agent and 100 proportions of distilled water are added in sequence by weight proportion, wetted, dispersed, ground, dispersed at high-speed, stirred, etc., so as to acquire the nano-composite antibacterial. The antibacterial can process the fiber product by a dip-dye method, a roll-dye method, a spray method, etc. Dresses, socks and socks, blankets, beddings, gowns, patient wears, masks, medicinal gauzes, air filtering nettings, etc., made from the inorganic / organic nano-composite antibacterial of the invention are characterized by high antibacterial efficiency, rapid antibacterial function, long lasting antibacterial performance, laundering durability, etc., and the inorganic / organic nano-composite antibacterial of the invention is applicable to life, medical care, etc., and has the functions of preventing the occurrence and transmission of diseases, protecting the health of people and improving life quality.

Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.

The present invention provides, in general, compositions comprising a hydrogel and an agent, for example a therapeutic agent or an imaging agent, for locoregional delivery. In certain preferred embodiments of the invention, the hydrogel compositions are detectable by Magnetic Responance and CT Scan and are used for locoregional delivery of therapeutic agents, for example chemotherapeutic agents. The invention also features polymer matrix compositions comprising nanoparticles that can be loaded after polymerization with bioactive agents, for example a diagnostic agent or therapeutic agent.

The present invention provides improved stents and other prostheses for delivering substances to vascular and other luminal and intracorporeal environments. In particular, the present invention provides for therapeutic capable agent eluting stents with minimized undesirable loss of the therapeutic capable agent during expansion of the stent.

The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.

Methods for preparing a series of mesoporous silicates, such as room-temperature ionic liquid (RTIL)-templated mesoporous silicate particles, with various particle morphologies are provided. Methods for preparing silicate particles with antimicrobial agents within the MSN pores is also provided. The particles can be used as controlled-release nanodevices to deliver antimicrobial agents.

The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.

A wireless repeater with features that improve the server-donor antenna isolation including multi-purpose server and donor mounting plates that each carry an antenna feed circuit board and associated antenna elements mounted in a back-to-back arrangement with the duplex repeater electronics board sandwiched between the server and donor mounting plates. To improve the server-donor antenna isolation, one or both mounting plates may include corner, side tabs, which may be asymmetric, and raised walls around one or both mounting plates. In addition, the radomes covering the donor antenna and / or the server antennas may carry one or more parasitic conductors, such as a two parasitic strips arranged in parallel lines or for parasitic strips arranged in a square configuration.

A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising a pharmaceutically active amphetamine salt covered with an immediate-release coating and a pharmaceutically active amphetamine salt covered with an enteric coating wherein the immediate release coating and the enteric coating provide for multiple pulsed dose delivery of the pharmaceutically active amphetamine salt. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.

The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

A stent capable of stably loading a biologically / physiologically active substance, without causing its decomposition or deterioration, and permitting it to release itself slowly over a long period of time without being rapidly released in a short period, after being implanted in a lesion. The stent (1) comprises a cylindrical stent main body (2) having an opening on each end and extending in axial direction between the two openings, and a sustained release coating formed on the surface of said stent main body from which a biologically / physiologically active substance is released, and wherein said sustained release coating is composed of a layer of a biologically / physiologically active substance (3) which covers the surface of said stent main body, and a polymer layer (4) which covers said layer of a biologically / physiologically active substance (3) on said layer of a biologically / physiologically active substance (3), and said layer of a biologically / physiologically active substance (3) contains at least one kind of fat-soluble biologically / physiologically active substance, and said polymer layer (4) contains a polymer miscible with said biologically / physiologically active substance and fine particles (5) equal to or smaller than 5 mum in particle diameter dispersed in the polymer.

A pharmaceutical formulation for delayed release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt. % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.5 hours; 5 to 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 1 hour; 10 to 75% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 2 hours; 15 to 82% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 3 hours; 30 to 97% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 6 hours; more than 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 12 hours; more than 70% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 18 hours, and more than 80% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 24 hours.

Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.

A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core.

A device for inducing weight loss in a patient includes a tubular prosthesis positionable at the gastro-esophageal junction region, preferably below the z-line. In a method for inducing weight loss, the prosthesis is placed such that an opening at its proximal end receives masticated food from the esophagus, and such that the masticated food passes through the pouch and into the stomach via an opening in its distal end.